In summary, prophylactic treatment with JES6/IL-2 complexes leads to an amelioration of SLE-like symptoms, whereas the prophylactic treatment with S4B6/IL-2 markedly aggravates disease symptoms when compared to mice with the untreated form of murine cGvHD. The gene discussed is IL2; the disease is systemic lupus erythematosus.